查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1553687

胰臟癌治疗市场规模、份额、趋势分析报告：按类型、治疗方法、最终用途、地区和细分市场预测，2024-2030

Pancreatic Cancer Treatment Market Size, Share & Trends Analysis Report By Type (Exocrine, Endocrine), By Treatment (Chemotherapy, Radiation Therapy, Others), By End-use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格
简介目录

胰臟癌治疗市场的成长和趋势

Grand View Research, Inc.最新报告显示，到2030年，全球胰臟癌治疗市场规模预计将达到69.8亿美元，预测期内复合年增长率为13.9%。

烟草消费、吸烟、肥胖的增加以及对各种可用治疗方案的认识不断提高正在推动全球市场的成长。胰臟癌的发病高峰年龄在65岁至75岁之间。因此，老年人口的增加预计也将推动预测期内的成长。

根据美国最危险的恶性之一，也是癌症死亡的第四大原因。此外，到 2030 年，胰臟癌预计将成为美国第二大死因。这些因素共同将推动预测期内的市场成长。

胰臟癌治疗市场报告亮点

  • 根据这项研究，外分泌胰臟癌是最常见的胰臟癌类型，占所有胰臟癌的95%以上。
  • 在治疗类型中，标靶治疗占据最大份额，因为它被认为是最有效的治疗选择。
  • 由于先进治疗方案的采用率很高和医疗保健基础设施高度发达，北美在 2023 年占据了最大的销售份额。
  • 预计亚太地区在预测期内将显着成长。主要原因是政府的倡议不断增加，人们对胰臟癌治疗方案的认识不断提高，以及用于有效治疗的高度先进的医疗基础设施的可用性。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章胰臟癌治疗市场变数、趋势和范围

  • 市场介绍/系统展望
  • 市场规模及成长前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 胰臟癌治疗分析工具
    • 波特的分析
    • PESTEL分析

第四章胰臟癌治疗市场：按类型估计和趋势分析

  • 细分仪表板
  • 胰臟癌治疗市场：类型变异分析，2024 年和 2030 年
  • 外分泌
  • 内分泌

第五章胰臟癌治疗市场：按治疗分类的估计和趋势分析

  • 细分仪表板
  • 胰臟癌治疗市场：2024 年和 2030 年治疗变化分析
  • 化疗
  • 放射治疗
  • 其他的

第六章胰臟癌治疗市场：最终用途的估计和趋势分析

  • 细分仪表板
  • 胰臟癌治疗市场：2024 年和 2030 年最终用途变化分析
  • 医院药房
  • 零售药房
  • 其他的

第七章胰臟癌治疗市场：区域估计与趋势分析

  • 2024 年和 2030 年按地区分類的胰臟癌治疗市场占有率，百万美元
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 挪威
    • 瑞典
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特
    • 南非

第八章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司分类
  • 企业热力图分析
  • 公司简介
    • AstraZeneca
    • Novartis AG
    • Pfizer Inc.
    • Genentech, Inc.
    • Bristol-Myers Squibb Company
    • Ipsen Pharma
    • Oncolytics Biotech Inc
    • TME Pharma
    • Phaxiam
简介目录
Product Code: GVR-1-68038-774-2

Pancreatic Cancer Treatment Market Growth & Trends:

The global pancreatic cancer treatment market size is expected to reach USD 6.98 billion by 2030, registering a CAGR of 13.9% during the forecast period, according to a new report by Grand View Research, Inc. Increasing tobacco consumption, smoking, obesity, and growing awareness pertaining to various treatment options available are propelling the market growth at a global level. The peak incidence of pancreatic cancer is seen in the age group of 65 to 75 years. Thus, growing geriatric population is also expected to drive the growth during the forecast period.

According to an article published in the National Center for Biotechnology Information in 2015, pancreatic cancer is one of the most dangerous malignancies and is the fourth most common cause of cancer deaths in the U.S. Furthermore, pancreatic cancer is expected to be the second common cause of death in the U.S., by 2030. These factors together would propel the market growth in the forecast period.

Pancreatic Cancer Treatment Market Report Highlights:

  • The study suggests that exocrine cancer is by far the most common type of pancreatic cancer accounting for more than 95% of the overall pancreatic cancer types.
  • Among the treatment types, targeted therapy occupied the largest share since it is considered as the most effective treatment option, which blocks the growth and spread of cancer cells without damaging healthy cells.
  • North America dominated the segment with the largest revenue share in 2023 due to high adoption rate of advanced treatment options and highly developed healthcare infrastructure.
  • Asia Pacific is anticipated to show a significant growth during the forecast period, mainly due to increasing government initiatives, growing awareness regarding the treatment options for pancreatic cancer, and the availability of highly sophisticated medical infrastructure for effective treatment.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Pancreatic Cancer Treatment Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Pancreatic Cancer Treatment Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Pancreatic Cancer Treatment Market: By Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Pancreatic Cancer Treatment Market: By Type Analysis, 2024 & 2030 (USD Million)
  • 4.3. Exocrine
    • 4.3.1. Exocrine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Endocrine
    • 4.4.1. Endocrine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Pancreatic Cancer Treatment Market: Treatment Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Pancreatic Cancer Treatment Market: By Treatment Analysis, 2024 & 2030 (USD Million)
  • 5.3. Chemotherapy
    • 5.3.1. Chemotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Radiation Therapy
    • 5.4.1. Radiation Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Others
    • 5.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Pancreatic Cancer Treatment Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Pancreatic Cancer Treatment Market: End Use Movement Analysis, 2024 & 2030 (USD Million)
  • 6.3. Hospital Pharmacies
    • 6.3.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Retail Pharmacies
    • 6.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Others
    • 6.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Pancreatic Cancer Treatment Market: Regional Estimates & Trend Analysis

  • 7.1. Pancreatic Cancer Treatment Market Share, By Region, 2024 & 2030, USD Million
  • 7.2. North America
    • 7.2.1. North America Pancreatic Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Pancreatic Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Pancreatic Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Pancreatic Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Pancreatic Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Pancreatic Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Pancreatic Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Pancreatic Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Pancreatic Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Pancreatic Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Pancreatic Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8. Norway
      • 7.3.8.1. Norway Pancreatic Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9. Sweden
      • 7.3.9.1. Sweden Pancreatic Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Pancreatic Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. China
      • 7.4.2.1. China Pancreatic Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Japan
      • 7.4.3.1. Japan Pancreatic Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Pancreatic Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Pancreatic Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Australia Pancreatic Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Pancreatic Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Pancreatic Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Pancreatic Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Pancreatic Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Pancreatic Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. Saudi Arabia
      • 7.6.2.1. Saudi Arabia Pancreatic Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. UAE
      • 7.6.3.1. UAE Pancreatic Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. Kuwait
      • 7.6.4.1. Kuwait Pancreatic Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. South Africa
      • 7.6.5.1. South Africa Pancreatic Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. AstraZeneca
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. Novartis AG
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. Pfizer Inc.
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. Genentech, Inc.
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. Bristol-Myers Squibb Company
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. Ipsen Pharma
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. Oncolytics Biotech Inc
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. TME Pharma
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. Phaxiam
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives